1 not yet recruiting, 1 suspended. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 1, Suspended 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Primary Progressive Multiple Sclerosis (PPMS): new trials by email Literature Review of Primary Progressive Multiple Sclerosis (PPMS) trials Research Report on Primary Progressive Multiple Sclerosis (PPMS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy C-CAR168 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | AbelZeta Inc. | 119 | 2027-02-01 | 2026-10-13 |
| IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis IDP-023, Ocrelizumab, Interleukin-2 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS) | Phase 1 | Suspended | Indapta Therapeutics, INC. | 34 | 2026-06-30 | 2025-04-30 |
Multiple Sclerosis (2) · Multiple Sclerosis, Chronic Progressive (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Nervous System Diseases (1)
Chronic Disease (2) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Leukoencephalopathies (1) · Nervous System Diseases (1)
Cyclophosphamide (1) · Interleukin-2 (1) · Mesna (1) · aldesleukin (1) · fludarabine (1) · ocrelizumab (1)
AbelZeta Inc. (1) · Indapta Therapeutics, INC. (1)
United States (2)
Yihong Yao, PhD (1)